Pricing Log in Create free account

Actuate Therapeutics, Inc. (ACTU) vs Prima BioMed Ltd (IMMP)

Actuate Therapeutics, Inc. and Prima BioMed Ltd are both Biotechnology companies. Prima BioMed Ltd is the larger, with a market value of $19.8M against $18.0M — 1.1× the size. Across the 8 metrics below, Actuate Therapeutics, Inc. leads on 4 and Prima BioMed Ltd on 4.

Valuation

Metric ACTU IMMP Biotechnology median
P/E n/m — 10.60
P/S n/m n/m 9.40
P/B 7.72 0.05 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m n/m 9.02
Earnings yield (271.88%) — (32.88%)
Free cash flow yield (259.67%) (1,225.42%) (23.13%)

Profitability

Metric ACTU IMMP Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 2,457.65% 0.00% (51.96%)
Return on assets (336.18%) 0.00% (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ACTU IMMP Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) 67.48% 93.23% 29.88%
Revenue growth, 5-year CAGR — 40.79% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ACTU IMMP Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 1.25 2.97 4.97
Net debt to EBITDA 0.59 0.92 1.01

Dividend

Metric ACTU IMMP Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACTU IMMP Biotechnology median
Market cap 17.98m 19.83m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack